Confirmatory interleukin-1 receptor antagonist trial in severe sepsis

Interleukin-1 and interleukin-1 antagonism

1991 • 2,276 citations

Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

1990 • 1,143 citations

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

1990 • 1,095 citations

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1994 • 920 citations

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

1990 • 865 citations

Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome

1995 • 805 citations

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome

1994 • 714 citations

Improved Survival of Patients With Acute Respiratory Distress Syndrome (ARDS): 1983-1993

1995 • 700 citations

Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.

1991 • 589 citations

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.

1990 • 569 citations

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trial

1994 • 488 citations

A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbits

1991 • 435 citations

Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome

1993 • 397 citations

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

1992 • 338 citations

Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor

1991 • 262 citations

Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.

1988 • 247 citations

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial

1994 • 238 citations

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

1992 • 214 citations

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial

1994 • 204 citations

The Clinical Evaluation of New Drugs for Sepsis

1993 • 202 citations

Round table conference on clinical trials for the treatment of sepsis

1995 • 98 citations

Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits

1993 • 74 citations

Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function

1995 • 63 citations

Endotoxin and staphylococcus aureus enterotoxin a induce different patterns of cytokines

1992 • 60 citations

Why have new effective therapies for sepsis not been developed?

1994 • 58 citations

The Efficacy of Combination Immunotherapy in Experimental Pseudomonas Sepsis

1993 • 56 citations

Lessons learned from clinical trials of sepsis

1995 • 22 citations